Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

CAMP4 Therapeutics Corporation

35 indications, side-by-side phase, drug & LoA

$4.19

-0.03 (-0.71%)

D 25Pipeline Score Richly Valued Biotech · Clinical
Market Cap
234.19 M
EPS
-2.27
P/E Ratio
-
Value Trade
198.53 K
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    1.29 M

  • R&D Expenses

    10.16 M

  • Operating CF

    -10.98 M

  • Total Assets

    105.46 M

  • Total Liabilities

    74.56 M

  • Equity

    30.90 M

  • D/E Ratio

    12,345

3.92 %
Week
-1.96 %
1 Month
6.77 %
3 Month
27.04 %
6 Month
-59.59 %
5 Year
-59.59 %
All Time
Cash Data
Healthy

  • Cash Position

    99.21 M

  • Monthly Burn

    3.66 M

  • Runway

    26 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 7, 2026
Overview
Volume
41.03 K
52 Week Range
1.31 - 7.75
% held by Insiders
48.93 %
% held by Institutions
55.78 %
Enterprise Value
136.37 M
Total Shares
51.96 M
Short %
1.18 %
Float Shares
28.84 M
Company Description
HQ: ONE KENDALL SQUARE, CAMBRIDGE,...
Employees:48
https://www.camp4tx.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 1/2 data readout example
CMP-SYNGAP-01 SYNGAP1-related disorders
Phase 1/2
—
RNA-Based Therapies
Nervous System
CMP-SYNGAP-01 SYNGAP1-related disorders
Phase 1/2
—
RNA-Based Therapies
Nervous System
CMP-SYNGAP-01 SYNGAP1-related disorders
Phase 1/2
—
RNA-Based Therapies
Nervous System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D25
Pipeline Score
$18M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 26%
Micro Cap
(rank 671 of 905)
Percentile Rank
CAMP4 Therapeutics Corporation faces pipeline headwinds (25/100), with $70M risk-adjusted pipeline value, led by CMP-CPS-001 in Healthy Volunteers (Phase 1).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
CMP-CPS-001
Small molecule		Healthy VolunteersPhase 1NCT062476707% $70M ACTIVE NOT_RECRUITING 120 SLOW C (55) Dec 1, 2027LOW_RISKMEDIUM
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
CMP-SYNGAP-01
SYNGAP1-related disorders
Phase 1
2025-08-15
CMP-SYNGAP-01
SYNGAP1-related disorders
Phase 1
2025-08-15
CMP-SYNGAP-01
SYNGAP1-related disorders
Phase 1
2025-08-15
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in CAMP
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
CAMP
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CAMP
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CAMP
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
CAMP Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
CAMP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest CAMP4 Therapeutics Corporation (CAMP) News & Alerts
-
Sunday, June 14, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How CAMP ranks across every disease it competes in
No competitive intelligence available for CAMP.